🕵️ Arrowhead Pharmaceuticals, Inc. ($ARWR)
SEC insider & ownership activity, last 12 months · CIK 879407 · every row links its SEC filing
Over the last 12 months insiders sold $37.9M with no open-market buying against it. Christopher Anzalone sold $24.0M through a program of 7 sale notices averaging $3.4M (Dec–Jan). 3 planned sales are pending, the largest $934K (Daniel Apel). No red-flag 8-Ks in the window.
🚨 5 signals active —
planned-vs-executed verdicts, pre-event flags, and cluster context live in the
API and the
alerts bot.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 10 sellers, $37.9M (67 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Christopher Anzalone | 0 | – | 25 | $24.0M | Jan 2, 2026 |
| James Hamilton | 0 | – | 14 | $5.7M | Apr 23, 2026 |
| Patrick O'Brien | 0 | – | 12 | $3.1M | Jan 5, 2026 |
| Mauro Ferrari | 0 | – | 2 | $1.0M | Dec 26, 2025 |
| Michael Perry | 0 | – | 1 | $992K | Dec 5, 2025 |
| Daniel Apel | 0 | – | 3 | $934K | Apr 22, 2026 |
| Victoria Vakiener | 0 | – | 3 | $679K | Dec 19, 2025 |
| Adeoye Y. Olukotun | 0 | – | 3 | $677K | Dec 19, 2025 |
| William Waddill | 0 | – | 3 | $566K | Dec 19, 2025 |
| Lu Hongbo | 0 | – | 1 | $228K | May 12, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Blackrock, Inc. | 10.1% | 13G | Jul 27, 2026 | filing ↗ | |
| Avoro Capital Advisors LLC | 8.3% | 13G | Aug 14, 2025 | filing ↗ | |
| Behzad Aghazadeh | 8.3% | 13G | Aug 14, 2025 | filing ↗ | |
| FMR LLC | 5.2% | 13G | May 6, 2026 | filing ↗ | |
| Abigail P. Johnson | 5.2% | 13G | May 6, 2026 | filing ↗ | |
| Vanguard Portfolio Management | 5.2% | 13G | Apr 28, 2026 | filing ↗ | |
| Vanguard Capital Management | 5.0% | 13G | Apr 29, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Hongbo Lu | $228K | May 12, 2026 | filing ↗ |
| James Hamilton | $750K | Apr 23, 2026 | filing ↗ |
| Daniel Apel | $934K | Apr 22, 2026 | filing ↗ |
| James Hamilton | $642K | Mar 5, 2026 | filing ↗ |
| James Hamilton | $2.5M | Jan 5, 2026 | filing ↗ |
| Patrick O'Brien | $3.1M | Jan 5, 2026 | filing ↗ |
| Christopher Anzalone | $872K | Jan 2, 2026 | filing ↗ |
| Christopher Anzalone | $3.6M | Dec 29, 2025 | filing ↗ |
| Mauro Ferrari | $527K | Dec 26, 2025 | filing ↗ |
| Christopher Anzalone | $861K | Dec 22, 2025 | filing ↗ |
| Christopher Anzalone | $910K | Dec 19, 2025 | filing ↗ |
| William Waddill | $566K | Dec 19, 2025 | filing ↗ |
| Adeoye Olukotun | $677K | Dec 19, 2025 | filing ↗ |
| Victoria Vakiener | $679K | Dec 19, 2025 | filing ↗ |
| Christopher Anzalone | $5.4M | Dec 17, 2025 | filing ↗ |
| Christopher Anzalone | $3.4M | Dec 16, 2025 | filing ↗ |
| Christopher Anzalone | $9.0M | Dec 15, 2025 | filing ↗ |
| Michael Perry | $991K | Dec 5, 2025 | filing ↗ |
| Mauro Ferrari | $493K | Nov 28, 2025 | filing ↗ |
| James Hamilton | $700K | Oct 1, 2025 | filing ↗ |
| James C. Hamilton | $450K | Sep 12, 2025 | filing ↗ |
| James C. Hamilton | $375K | Sep 2, 2025 | filing ↗ |
| James C. Hamilton | $188K | Aug 15, 2025 | filing ↗ |
| James C. Hamilton | $12K | Aug 13, 2025 | filing ↗ |
| Sarepta Therapeutics, Inc. | $185.2M | Aug 13, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Officer/director changes (5.02) | Jun 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 12, 2026 | filing ↗ |
| Earnings (2.02) | May 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 7, 2026 | filing ↗ |
| Shareholder vote (5.07) | Mar 19, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 19, 2026 | filing ↗ |
| Earnings (2.02) | Feb 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 5, 2026 | filing ↗ |
| Material agreement (1.01) | Jan 12, 2026 | filing ↗ |
| New financial obligation (2.03) | Jan 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 12, 2026 | filing ↗ |
| Material agreement (1.01) | Jan 7, 2026 | filing ↗ |
| Other events (8.01) | Jan 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 7, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 6, 2026 | filing ↗ |
| Other events (8.01) | Jan 6, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 6, 2026 | filing ↗ |
| Earnings (2.02) | Nov 25, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 25, 2025 | filing ↗ |
| Other events (8.01) | Nov 18, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 18, 2025 | filing ↗ |
| Other events (8.01) | Sep 11, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 11, 2025 | filing ↗ |
| Other events (8.01) | Sep 10, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 10, 2025 | filing ↗ |
| Material agreement (1.01) | Sep 2, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 2, 2025 | filing ↗ |
| Earnings (2.02) | Aug 7, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 7, 2025 | filing ↗ |